Autologous Bone Marrow Cells With Wharton Gel Exosomes for Liver Cirrhosis
Official title: A New Regenerative Medicine Protocol Using Autologous Bone Marrow Mononuclear Cells With Growth Factors to Treat Liver Cirrhosis
Run by Global Stem Cell Center, Baghdad · NCT07374185 · Data updated 2026-11-12
Doctors are testing whether using a patient’s own bone marrow cells with Wharton gel exosomes can help the liver repair itself in people with liver cirrhosis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 80 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Global Stem Cell Center, Baghdad Industry-sponsored |
| Locations | 1 site (Baghdad, Iraq) |
| Status | Recruiting |
| Started | February 20, 2026 |
| Main results expected | December 20, 2026 |
| Study ends | December 20, 2026 |
| Registry record updated | September 15, 2026 |
| Trial ID | NCT07374185 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults under 80 with liver cirrhosis who do not have active cancer, sepsis, or pregnancy.
✕Probably not a fit
Patients with active life-threatening conditions, including malignancy or severe sepsis, may not benefit from this therapy.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study uses autologous bone marrow–derived mononuclear cells collected from the patient’s iliac crest, processed to concentrate viable cells, and combined with a small amount of Wharton gel exosomes before intravenous administration. The approach aims to support liver tissue repair in adults with cirrhosis who do not have active cancer or other life-threatening conditions. Enrollment includes adults under 80 with cirrhosis, excluding those with active malignancy, severe sepsis, or pregnancy. The study is led by Global Stem Cell Center in Baghdad and conducted at Capital Private Hospital in Iraq.
Why it matters
Potential benefit: If successful, participants may experience improved liver function or slowed progression of cirrhosis.
How similar studies have gone: Previous mesenchymal stem cell approaches for liver disease show potential, but this exact combination with Wharton gel exosomes is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: any patient with liver cirrhosis , less than 80 years of age - Exclusion Criteria: 1. active malignancy. 2. severe sepsis. 3. pregnancy. -
Where it's running
-
Capital Private Hospital Alrabee Street
Baghdad, Iraq, Iraq Recruiting
Study contacts
- Study coordinator: abdulmajeed hammadi
- Email: hammadimajeed@gmail.com
- Phone: +9647902268105
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using spleen size to help detect gastroesophageal varices in compensated cirrhosis
This study tests whether ultrasound measurements of spleen size can help identify esophageal varices in adults with compensated cirrhosis, compared with the standard endoscopy test.
-
Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen
This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.
-
Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS
A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.
-
Foscenvivint in HIV/HCV co-infected adults with liver cirrhosis and hemophilia
This study tests whether foscenvivint can help people with liver cirrhosis due to HIV/HCV co-infection who also have hemophilia.
-
Austrian PBC Registry
This registry follows adults with primary biliary cholangitis in Austrian centers to see how the disease develops over time and how biomarkers relate to complications and symptoms.
-
Reference framework for outcomes after machine-preserved liver transplantation in Europe
This study tests how liver transplants that use machine perfusion perform in real-world practice, to see how different perfusion methods relate to outcomes for adults in Europe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.